JP2001508034A - 鼻ポリープの治療におけるh▲上+▼,k▲上+▼―atpアーゼ阻害剤の使用 - Google Patents
鼻ポリープの治療におけるh▲上+▼,k▲上+▼―atpアーゼ阻害剤の使用Info
- Publication number
- JP2001508034A JP2001508034A JP51824698A JP51824698A JP2001508034A JP 2001508034 A JP2001508034 A JP 2001508034A JP 51824698 A JP51824698 A JP 51824698A JP 51824698 A JP51824698 A JP 51824698A JP 2001508034 A JP2001508034 A JP 2001508034A
- Authority
- JP
- Japan
- Prior art keywords
- glucocorticoid
- atpase inhibitor
- pharmaceutical formulation
- treating
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.鼻ポリープを治療するための医薬の製造における、H+,K+−ATPアーゼ阻害剤 の使用。 2.ヴィダル症候群を治療するための医薬の製造におけるH+,K+−ATPアーゼ阻害 剤の使用。 3.ヴィダル症候群の治療で、同時に、別々にまたは連続して投薬することを意 図する、医薬処方物の製造におけるH+,K+−ATPアーゼ阻害剤およびグルココルチ コイドの使用。 4.喘息の治療で、同時に、別々にまたは連続して投薬することを意図する、医 薬処方物の製造におけるH+,K+−ATPアーゼ阻害剤およびグルココルチコイドの使 用。 5.グルココルチコイドが局所活性な抗炎症ステロイドである、請求項3の使用 。 6.グルココルチコイドがブデソニド、ジプロピオン酸ベクロメタゾンまたはプ ロピオン酸フルチカゾンである、請求項4の使用。 7.H+,K+−ATPアーゼ阻害剤が、式 (式中、Het1は であり、Het2は であり、そしてXは であり、ここでHet2のベンズイミダゾール部分中のNは、R6〜R9によって置換さ れている環炭素原子の一つが、場合によりなんらの置換基を持たない窒素原子と 交換されていてもよいことを示しており、 R1およびR3は、R1およびR3が同時にアルコキシを表すことはないという条件で 、それぞれ独立して水素、アルキル、またはアルコキシを表し、そしてR2はアル キル、場合によりフッ素で置換されたアルコキシ、アルキルチオまたはアルコキ シアルコキシを表すか、またはR1およびR3の一方はハロゲンであり、もう一方は 水素であり、そしてR2は1−モルホリノ、1−ピペリジノまたはジアルキルアミ ノであり、 R4およびR5は、同じかまたは異なり、水素およびアルキルから選ばれ、 R6〜R9は同じかまたは異なり、水素、ハロゲン、アルキル、アルコキシ、ハロ アルコキシ、アルキルカルボニルおよびアルコキシカルボニルから選ばれ、 R10は水素であるか、またはR10とR3は一緒になって6〜8個の炭素原子を含む 環を形成し、そして R11は水素、ハロゲンまたはアルキルを表し、 ここで、式(I)の化合物は、場合により医薬上許容しうるアルカリ塩の形態も しくは中性の形態であるか、または単一の鏡像異性体もしくはそのラセミ混合物 であり、 式中、アルキルまたはアルケニル部分の夫々は、枝分かれ鎖または直鎖であっ て、1〜6個の炭素原子を有する) の化合物である、前記請求項のいずれか一項に記載の使用。 8.式(I)の化合物が、式の化合物、そのアルカリ塩、または(−)−鏡像異性体もしくは(−)−鏡像異性体 のアルカリ塩である、請求項7の使用。 9.鼻ポリープの病気にかかっている患者に、H+,K+−ATPアーゼ阻害剤を含む医 薬処方物を用いて治療することからなる、鼻ポリープを治療するための方法。 10.ヴィダル症候群の病気にかかっている患者に、H+,K+−ATPアーゼ阻害剤を含 む医薬処方物を用いて治療することからなる、ヴィダル症候群を治療するための 方法。 11.ヴィダル症候群の病気にかかっている患者に、H+,K+−ATPアーゼ阻害剤およ びグルココルチコイドを含む医薬処方物を、同時に、別々に、または連続して投 薬することからなる、ヴィダル症候群を治療するための方法。 12.喘息の病気にかかっている患者に、H+,K+−ATPアーゼ阻害剤およびグルココ ルチコイドを含む医薬処方物を、同時に、別々に、または連続して投薬すること からなる、喘息を治療するための方法。 13.グルココルチコイドが請求項5または6で定義されたグルココルチコイドで ある、請求項11の方法。 14.H+,K+−ATPアーゼ阻害剤が、請求項7または8で定義した式の化合物である 、請求項9〜13のいずれか一項の方法。 15.ヴィダル症候群の治療において、H+,K+−ATPアーゼ阻害剤およびグルココル チコイドを含む処方物を、同時に、別々にまたは連続して使用するた めの医薬処方物。 16.喘息の治療において、H+,K+−ATPアーゼ阻害剤およびグルココルチコイドを 含む処方物を、同時に、別々にまたは連続して使用するための医薬処方物。 17.グルココルチコイドが、請求項5または6で定義したグルココルチコイドで ある、請求項15または16の医薬処方物。 18.H+,K+−ATPアーゼ阻害剤が、請求項7または8で定義した式の化合物である 、請求項15〜17のいずれか一項の医薬処方物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9603725-4 | 1996-10-11 | ||
SE9603725A SE9603725D0 (sv) | 1996-10-11 | 1996-10-11 | New teatment |
PCT/SE1997/001651 WO1998016228A1 (en) | 1996-10-11 | 1997-10-01 | USE OF AN H+, K+-ATPase INHIBITOR IN THE TREATMENT OF NASAL POLYPS |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001508034A true JP2001508034A (ja) | 2001-06-19 |
JP2001508034A5 JP2001508034A5 (ja) | 2005-06-16 |
JP4100713B2 JP4100713B2 (ja) | 2008-06-11 |
Family
ID=20404214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51824698A Expired - Fee Related JP4100713B2 (ja) | 1996-10-11 | 1997-10-01 | 鼻ポリープの治療におけるh▲上+▼,k▲上+▼―atpアーゼ阻害剤の使用 |
Country Status (34)
Country | Link |
---|---|
EP (1) | EP0946175B1 (ja) |
JP (1) | JP4100713B2 (ja) |
KR (1) | KR100510812B1 (ja) |
CN (1) | CN1146416C (ja) |
AR (1) | AR008886A1 (ja) |
AT (1) | ATE230597T1 (ja) |
AU (1) | AU738310B2 (ja) |
BR (1) | BR9711896A (ja) |
CA (1) | CA2268305C (ja) |
CZ (1) | CZ298799B6 (ja) |
DE (1) | DE69718347T2 (ja) |
DK (1) | DK0946175T3 (ja) |
EE (1) | EE04043B1 (ja) |
ES (1) | ES2188995T3 (ja) |
HK (1) | HK1022848A1 (ja) |
HU (1) | HUP0000036A3 (ja) |
ID (1) | ID23692A (ja) |
IL (1) | IL129324A0 (ja) |
IS (1) | IS1930B (ja) |
MY (1) | MY117918A (ja) |
NO (1) | NO321007B1 (ja) |
NZ (1) | NZ334786A (ja) |
PL (1) | PL190902B1 (ja) |
PT (1) | PT946175E (ja) |
RS (1) | RS49599B (ja) |
RU (1) | RU2197966C2 (ja) |
SA (1) | SA97180641B1 (ja) |
SE (1) | SE9603725D0 (ja) |
SK (1) | SK284252B6 (ja) |
TR (1) | TR199900770T2 (ja) |
TW (1) | TW568784B (ja) |
UA (1) | UA59374C2 (ja) |
WO (1) | WO1998016228A1 (ja) |
ZA (1) | ZA978842B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6846799B1 (en) * | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
DE69939022D1 (de) | 1998-08-18 | 2008-08-14 | Univ California | Epidermale wachstumsfaktor rezeptor antagonisten zur behandlung stark vermehrter schleimsekretion in der lunge |
US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
AU2002342917A1 (en) * | 2001-11-19 | 2003-06-10 | Altana Pharma Ag | Reversible proton pump inhibitors for the treatment of airway disorders |
PL370839A1 (en) * | 2002-03-14 | 2005-05-30 | Altana Pharma Ag | Use of proton pump inhibitors for the treatment of airway disorders |
US20050222193A1 (en) * | 2002-05-07 | 2005-10-06 | Guido Hanauer | Novel combination for the treatment of airway disorders |
NZ536918A (en) * | 2002-05-07 | 2006-09-29 | Altana Pharma Ag | Combination of pantoprazole and a respiratory agent for the treatment of respiratory diseases |
FR2845915B1 (fr) * | 2002-10-21 | 2006-06-23 | Negma Gild | Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien |
JP4755495B2 (ja) | 2002-12-12 | 2011-08-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 組合せ医薬品 |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
PT1670482E (pt) | 2003-09-16 | 2014-03-12 | Takeda Gmbh | Utilização de ciclesonida para o tratamento de doenças respiratórias |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
CN104408249B (zh) * | 2014-11-24 | 2017-09-26 | 广州供电局有限公司 | 单芯电缆导体热性参数的确定方法及*** |
KR101974504B1 (ko) * | 2017-04-10 | 2019-05-03 | 재단법인 아산사회복지재단 | 호산구성 비용종 동물모델 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1429184A (en) * | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
GB1571629A (en) * | 1977-11-30 | 1980-07-16 | Fisons Ltd | Pharmaceutical compositions containing beclomethasone dipropionate |
-
1996
- 1996-10-11 SE SE9603725A patent/SE9603725D0/xx unknown
-
1997
- 1997-01-10 UA UA99042004A patent/UA59374C2/uk unknown
- 1997-10-01 SK SK384-99A patent/SK284252B6/sk unknown
- 1997-10-01 CZ CZ0122999A patent/CZ298799B6/cs not_active IP Right Cessation
- 1997-10-01 PT PT97945135T patent/PT946175E/pt unknown
- 1997-10-01 DK DK97945135T patent/DK0946175T3/da active
- 1997-10-01 KR KR10-1999-7003115A patent/KR100510812B1/ko not_active IP Right Cessation
- 1997-10-01 TR TR1999/00770T patent/TR199900770T2/xx unknown
- 1997-10-01 WO PCT/SE1997/001651 patent/WO1998016228A1/en active IP Right Grant
- 1997-10-01 RS YUP-163/99A patent/RS49599B/sr unknown
- 1997-10-01 HU HU0000036A patent/HUP0000036A3/hu unknown
- 1997-10-01 ES ES97945135T patent/ES2188995T3/es not_active Expired - Lifetime
- 1997-10-01 EE EEP199900118A patent/EE04043B1/xx not_active IP Right Cessation
- 1997-10-01 AU AU46409/97A patent/AU738310B2/en not_active Ceased
- 1997-10-01 AT AT97945135T patent/ATE230597T1/de not_active IP Right Cessation
- 1997-10-01 NZ NZ334786A patent/NZ334786A/xx unknown
- 1997-10-01 EP EP97945135A patent/EP0946175B1/en not_active Expired - Lifetime
- 1997-10-01 RU RU99109596/14A patent/RU2197966C2/ru not_active IP Right Cessation
- 1997-10-01 DE DE69718347T patent/DE69718347T2/de not_active Expired - Fee Related
- 1997-10-01 JP JP51824698A patent/JP4100713B2/ja not_active Expired - Fee Related
- 1997-10-01 CN CNB971985847A patent/CN1146416C/zh not_active Expired - Fee Related
- 1997-10-01 PL PL332692A patent/PL190902B1/pl not_active IP Right Cessation
- 1997-10-01 CA CA002268305A patent/CA2268305C/en not_active Expired - Fee Related
- 1997-10-01 IL IL12932497A patent/IL129324A0/xx not_active IP Right Cessation
- 1997-10-01 BR BR9711896A patent/BR9711896A/pt not_active Application Discontinuation
- 1997-10-01 ID IDW990139D patent/ID23692A/id unknown
- 1997-10-02 ZA ZA9708842A patent/ZA978842B/xx unknown
- 1997-10-07 TW TW086114622A patent/TW568784B/zh not_active IP Right Cessation
- 1997-10-07 MY MYPI97004697A patent/MY117918A/en unknown
- 1997-10-08 AR ARP970104655A patent/AR008886A1/es unknown
- 1997-11-23 SA SA97180641A patent/SA97180641B1/ar unknown
-
1999
- 1999-04-06 NO NO19991619A patent/NO321007B1/no unknown
- 1999-04-08 IS IS5021A patent/IS1930B/is unknown
-
2000
- 2000-04-03 HK HK00102015A patent/HK1022848A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060025450A1 (en) | Use of an H+, K+ -ATPase inhibitor in the treatment of asthma | |
JP4100713B2 (ja) | 鼻ポリープの治療におけるh▲上+▼,k▲上+▼―atpアーゼ阻害剤の使用 | |
IL216932A (en) | Composition of pharmaceuticals containing azalastine and cyclozonide and method for the manufacture of a periodic allergy treatment containing this composition | |
IT9048260A1 (it) | Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione. | |
JP2001526210A (ja) | 親油性糖質副腎皮質ステロイドおよび界面活性剤を1つだけ含有するミセルを含んでなる医薬組成物 | |
JP2016510012A (ja) | Maba化合物およびコルチコステロイドを含む組合せ剤 | |
JP2016527245A (ja) | Maba化合物およびコルチコステロイドを含む組合せ剤 | |
JP4976139B2 (ja) | 処置方法 | |
WO2000053187A1 (en) | New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd | |
WO2001012191A2 (en) | Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid | |
US9636350B2 (en) | Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041001 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041001 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080318 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |